Related Experiment Video
Updated: Jun 3, 2026
06:21
Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
[Progress in the study of UDP-glucuronosyltransferase gene polymorphism]
Dong Guo1, Liang-Fang Pang, Hong-Hao Zhou
1Institute of Clinical Pharmacology, Xiang-Ya Medical College, Central South University, Changsha 410078, China.
Sheng Li Ke Xue Jin Zhan [Progress in Physiology]
|March 23, 2011
Summary
Uridinediphosphoglucuronate-glucuronosyltransferase (UGT) is vital for metabolizing toxins. UGT1A gene variations explain differences in how individuals process glucuronic acid, impacting drug and toxin metabolism.
Area of Science:
- Biochemistry
- Pharmacogenomics
- Enzymology
Context:
- Uridinediphosphoglucuronate-glucuronosyltransferase (UGT) is a critical Phase II metabolic enzyme.
- UGTs are prevalent in the liver, kidney, and intestines, processing numerous endogenous and exogenous compounds.
- Genetic variations in UGT1A significantly contribute to inter-individual differences in glucuronidation.
Purpose:
- To review the current understanding of UGT enzymes.
- To highlight recent advancements in UGT gene mutation research.
- To explore the clinical implications of UGT genetic polymorphisms.
Summary:
- This review focuses on Uridinediphosphoglucuronate-glucuronosyltransferase (UGT), a key enzyme in Phase II metabolism.
- It discusses the role of UGTs in metabolizing diverse substances across various tissues.
- The paper emphasizes UGT1A genetic polymorphism as a major factor in variable glucuronic acid metabolism among individuals.
Impact:
- Understanding UGT gene mutations is crucial for personalized medicine.
- This knowledge can optimize drug therapy by predicting metabolic rates.
- It aids in managing conditions influenced by altered glucuronidation pathways.
Related Concept Videos
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:24Phase II Reactions: Glucuronidation
Glucuronidation, a pivotal phase II biotransformation process, involves the coupling of glucuronic acid to a drug or xenobiotic. Given its widespread occurrence and critical role in drug metabolism, it's considered the most crucial phase II reaction. It enhances the water solubility of substances, aiding their expulsion from the body. The driving force behind these reactions is a group of enzymes known as UDP-glucuronosyltransferases (UGTs). UGTs facilitate the transfer of a glucuronic acid...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...